AbbVie’s been cranking up the heat on Biohaven’s oral migraine med Nurtec with its rival Qulipta. Biohaven’s solution? Take the competition overseas.
Nurtec — or rimegepant, as it’s known chemically — is now the first drug approved in the EU for both acute and prophylactic treatment of migraines, where it...
